SCHEMBL2850327

SCHEMBL2850327

CCC(N)(C(=O)O)C(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.50
HIF1A Q16665 1/20 0.50
CES1 P23141 7/20 0.45
CYP1A2 P05177 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CES2 O00748 4/20 0.42
SRC P12931 1/20 0.42
CTNNB1 P35222 1/20 0.41
CYP3A4 P08684 2/20 0.40
MAPT P10636 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
CYP2C19 P33261 2/20 0.40
TSHR P16473 2/20 0.40
POLB P06746 1/20 0.40
PARP1 P09874 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2159286 0.85 SMN1; SMN2 (0.47) SMN1; SMN2HIF1ACES1CYP1A2MEN1
SCHEMBL10616915 0.82 HIF1A (0.52) SMN1; SMN2HIF1ACES1MEN1KMT2A
SCHEMBL1507308 0.82 HIF1A (0.52) SMN1; SMN2HIF1ACES1CYP1A2MEN1
SCHEMBL1507309 0.82 HIF1A (0.52) SMN1; SMN2HIF1ACES1CYP1A2MEN1
SCHEMBL10662179 0.82 CES1 (0.45) SMN1; SMN2HIF1ACES1KMT2ACES2
SCHEMBL11403866 0.82 CES1 (0.45) SMN1; SMN2HIF1ACES1KMT2ACES2
SCHEMBL27717847 0.82 LMNA (0.51) SMN1; SMN2CYP1A2KMT2ACYP3A4TDP1
SCHEMBL28194587 0.81 SMN1; SMN2 (0.47) SMN1; SMN2HIF1ACES1CYP1A2MEN1
SCHEMBL4878730 0.81 SMN1; SMN2 (0.50) SMN1; SMN2HIF1ACES1CYP1A2MEN1
SCHEMBL2161616 0.81 HIF1A (0.50) SMN1; SMN2HIF1ACES1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010019469-A2 PREPARATION OF (S)-2-AMINOBUTYRIC ACID DR. REDDY'S LABORATORIES LTD. (IN) 2010-02-18 WO claimed
EP-3878287-B1 APPLICATION OF ACYLATED DERIVATIVE OF AMINO ACID IN PREPARATION OF ANIMAL FEED ADDITIVE PENG XIANFENG (CN) 2026-03-11 EP disclosed
US-20250241340-A1 APPLICATION OF ACYLATED DERIVATIVE OF AMINO ACID IN PREPARATION OF ANIMAL FEED ADDITIVE Anipha Technologies Pty Ltd (AU) 2025-07-31 US disclosed
US-20220007684-A1 APPLICATION OF ACYLATED DERIVATIVE OF AMINO ACID IN PREPARATION OF ANIMAL FEED ADDITIVE Anipha Technologies Pty Ltd (AU) 2022-01-13 US disclosed
EP-3878287-A1 APPLICATION OF ACYLATED DERIVATIVE OF AMINO ACID IN PREPARATION OF ANIMAL FEED ADDITIVE Peng, Xianfeng (CN) 2021-09-15 EP disclosed
CN-109070051-A Composite mode adsorbing medium, its method made and used with composite mode ligand 赛多利斯司特蒂姆生物工艺公司 2018-12-21 CN disclosed
US-20100105681-A1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS LASSOIE MARIE-AGNES 2010-04-29 US disclosed
US-7638630-B2 Very Late Antigen-4 dependent inflammatory disease; asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders, autoimmune disorders, or atherosclerosis, inflammatory skin disorder; methyl 3-[2-(2,6-dichlorophenyl)-6-quinolinyl]-2-hydroxy-2-propenoate UCB PHARMA S.A. (BE) 2009-12-29 US disclosed
US-20080064720-A1 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors UCB, S.A. (BE) 2008-03-13 US disclosed
WO-1999020606-A2 PIPERIDINES AND PIPERAZINES AS PLATELET AGGREGATION INHIBITORS J. URIACH & CIA. S.A. (ES) 1999-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064720-A1 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors VCAM1, HRH4, LTA4H SMN1; SMN2 4507/4885HIF1A 2406/4885CES1 960/4885
US-20100105681-A1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS SCN4A, NECTIN4, VPS4B SMN1; SMN2 3831/4885HIF1A 3415/4885CES1 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.